Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-11-29 Remuneration Information
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司关于2021年限制性股票激励计划（草案）及相关文件的修订说明公告
Remuneration Information Classification · 95% confidence The document is an announcement from Chengdu Lead Drug Development Co., Ltd. regarding revisions to its 2021 Restricted Stock Incentive Plan (draft). It details changes in the number of shares granted, adjustments to the incentive recipients, and accounting treatments related to the stock incentive plan. The content focuses on stock-based compensation and incentive plan adjustments, which are related to remuneration and compensation information for executives and key personnel. There is no indication that this is a full annual report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement. The document is not a regulatory filing or a general announcement but specifically relates to executive compensation plans. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length and detail support this classification with high confidence.
2021-11-29 Chinese
成都先导药物开发股份有限公司2021年限制性股票激励计划激励对象名单（调整后）
Remuneration Information Classification · 95% confidence The document is titled as a list of incentive recipients under a 2021 restricted stock incentive plan for Chengdu Lead Pharmaceuticals Co., Ltd. It contains detailed tables listing individuals and their allocated restricted stock quantities, including senior management and other personnel. The content focuses on stock incentive allocations and related disclosures, which are related to remuneration and compensation plans for executives and key employees. There is no financial statement data, no audit information, no voting results, no legal proceedings, no earnings data, and no presentation or report publication announcement. The document is a detailed disclosure of stock-based compensation allocations, which fits the definition of Remuneration Information (DEF 14A) filings that detail compensation for top executives and directors. The document length is 4341 characters, which is sufficient for a detailed remuneration disclosure rather than a brief announcement. Therefore, the best classification is Remuneration Information (DEF 14A).
2021-11-29 Chinese
成都先导药物开发股份有限公司独立董事关于第一届董事会第十九次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on proposals related to the company's 2021 restricted stock incentive plan and its implementation assessment management measures. It discusses compliance with laws and regulations, the reasonableness of the incentive plan, and its benefits to the company and shareholders. The document is a formal opinion related to board meeting proposals, not a full report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a regulatory announcement or certification. It is related to board/management information concerning incentive plans and governance matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on board opinions, not a full report or announcement.
2021-11-29 Chinese
成都先导药物开发股份有限公司关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement regarding the public solicitation of proxy voting rights by an independent director for a company's upcoming extraordinary general meeting (EGM) to be held on December 16, 2021. It details the voting period, the agenda items related to a 2021 restricted stock incentive plan, the procedures for shareholders to submit proxy votes, and includes an authorization form for shareholders to delegate their voting rights. The document does not contain financial statements or results, nor is it a report or transcript. It is a formal announcement related to voting rights and proxy solicitation for a shareholder meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 4480 characters, which is consistent with a detailed announcement rather than a full report.
2021-11-29 Chinese
成都先导药物开发股份有限公司2021年限制性股票激励计划（草案修订稿）
Remuneration Information Classification · 95% confidence The document is a detailed announcement and explanation of a 2021 restricted stock incentive plan (股权激励计划) for Chengdu Lead Drug Development Co., Ltd. It includes legal references, plan purpose, management structure, scope of incentive recipients, stock allocation, vesting conditions, performance targets, and implementation procedures. The content focuses on the company's stock-based employee incentive plan, including detailed terms and conditions, pricing, and governance. This type of document is related to executive and employee remuneration and compensation plans, specifically stock incentives. It is not a financial report, earnings release, or regulatory filing about financial results or corporate governance changes. It is not a proxy statement or voting results announcement. It is a remuneration-related disclosure about stock incentives for management and key personnel. Therefore, the most appropriate classification is Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2021-11-29 Chinese
上海荣正投资咨询股份有限公司关于公司2021年限制性股票激励计划（草案修订稿）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a 2021 restricted stock incentive plan for Chengdu Lead Pharma Development Co., Ltd. It contains detailed sections on definitions, statements, assumptions, and the main content of the incentive plan including scope, allocation, stock quantities, vesting conditions, and performance criteria. The content is a professional advisory report analyzing the stock incentive plan's compliance, feasibility, and financial impact. It is not a general annual or quarterly financial report, nor is it a simple announcement or voting result. It is a specialized advisory report related to a capital incentive plan, which fits best under the category of Capital/Financing Update (CAP) because it deals with stock issuance and equity incentives as a form of capital structure change and financing activity. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the classification is CAP with high confidence.
2021-11-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.